CTC 96

Drug Profile

CTC 96

Alternative Names: CTC-96; Doxovir

Latest Information Update: 21 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Redox Pharmaceutical
  • Developer OPKO Health; Redox Pharmaceutical
  • Class Antivirals; Nonsteroidal anti-inflammatories; Organometallic compounds; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Herpes simplex virus infections; Infectious keratoconjunctivitis

Most Recent Events

  • 12 Jun 2008 Phase-II development is ongoing
  • 12 Jun 2008 CTC 96 licensed to OPKO Health worldwide for ophthalmological applications
  • 25 Aug 2004 Two preclinical studies have been added to the Viral Infections antimicrobial activity section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top